FDA approves Pfizer-BioNTech's Omicron KP.2 vaccine for immunity against the subvariant.
The FDA has granted approval for Pfizer-BioNTech's Omicron KP.2 COVID-19 vaccine, designed to provide immunity against the Omicron subvariant. The vaccine has undergone rigorous testing and evaluation to ensure its safety and efficacy in protecting individuals from the KP.2 strain. Its availability is expected to help curb the spread of the Omicron variant and its sublineages.
August 22, 2024
449 Articles